Portable, Pocket-Sized A1c Testing Device Delivers Results in 5 Minutes From Single Blood Drop

Diabetes stands as a primary contributor to mortality rates and accounts for a significant portion of healthcare expenses, primarily related to diabetes-related comorbidities. These comorbidities can range from neurological and cardiovascular to renal issues and chronic kidney disease (CKD). Consequently, it is crucial to ensure patients have adequate access to HbA1c testing. Point-of-care (POC) A1c devices can efficiently and accurately determine patients' A1c levels, offering an affordable and user-friendly option for healthcare professionals of all backgrounds and experience levels. Now, a cutting-edge portable glycated hemoglobin analyzer employs single-cell analysis of red blood cells to provide immediate and precise HbA1c testing at POC, facilitating real-time diagnosis and monitoring of diabetes.

The OBM rapid A1c from Orange Biomed (Seoul, South Korea) is a compact, portable A1c testing device that requires just a single drop of blood. This user-friendly, palm-sized device does not require prior training or experience, making it ideal for addressing crucial testing needs for individuals with pre-diabetes and diabetes. Utilizing microfluidic technology, the OBM Rapid A1c remains unaffected by potential inconsistencies in sampling volume, and its test results are not influenced by hemoglobin variants, unlike other POC tests. This pioneering approach ensures accurate assessment every time, regardless of the test administrator or recipient.

Besides its portability and exceptional accuracy, the OBM Rapid A1c meter boasts an unlimited shelf life, and its cartridges remain functional for two years. The meter can be reused without the need for maintenance or calibration, making it an ideal all-in-one solution for primary care physicians, endocrinologists, and cardiologists. The reusable system allows healthcare professionals to quickly test multiple patients, streamlining the process across healthcare environments. The OBM Rapid A1c is currently undergoing global studies, and Orange Biomed aims to obtain FDA clearance within the next year.

“OBM rapid A1c is a portable, guided, five-minute test requiring only a single drop of blood to produce accurate results,” said Orange Biomed co-founder Yeaseul Park. “By seamlessly integrating lab-level technology into portable devices, we seek to make healthcare more accessible, accurate, and affordable for everyone.”

Related Links:
Orange Biomed